Skip to main content
Clinical Trials/NCT06566625
NCT06566625
Recruiting
Not Applicable

The Karolinska Pilot Study for Cardiac Magnetic Resonance Imaging Prior to Invasive Coronary Angiography in Patients With Suspected Non-ST-Elevation Myocardial Infarction

Region Stockholm1 site in 1 country150 target enrollmentJuly 17, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-ST Elevation Myocardial Infarction
Sponsor
Region Stockholm
Enrollment
150
Locations
1
Primary Endpoint
Rate of IRA territory reclassification
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Patients with a suspected myocardial infarction are subdivided into ST-elevation and non-ST-elevation myocardial infarctions (STEMI and NSTEMI, respectively) using an ECG. While patients with STEMI are urgently referred to a cath lab, patients with NSTEMI usually undergo a planned invasive coronary angiography (ICA) anywhere from 24-72 hours after arriving to the hospital. When an invasive coronary angiography can not explain the cause of a myocardial infarction, an MRI of the heart (a CMR) is often done as a follow-up investigation.

A growing body of evidence suggests that performing a CMR before the planned ICA can provide an accurate diagnosis and defer the need for an ICA in many of these patients with NSTEMI.

Detailed Description

KaPSICA-CMR is an observational pilot study at the Karolinska University Hospital which aims to validate, in a Swedish healthcare setting, the potentials of a CMR-first approach in patients with suspected NSTEMI. We plan on including 150 patients, both with (n=50) and without (n=100) previous myocardial infarction. In addition to a standard clinical CMR protocol, the study will test novel CMR techniques such as magnetic resonance angiography and magnetic resonance fingerprinting sequences in this cohort. Patients will be recruited at both the Solna- and Huddinge sites of the hospital and include patients referred to ICA from the Visby- and Södertälje hospitals. The findings on the CMR will be blinded to treating physicians, with exceptions for unexpected adverse findings. In the event that a CMR would be indicated in line with clinical practice, the CMR findings are unblinded.

Registry
clinicaltrials.gov
Start Date
July 17, 2024
End Date
December 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ≥18 years of age Suspected NSTEMI (signs and symptoms suggest of ACS with initial ECG showing no ST-elevation)
  • Planned ICA where CMR can be performed without delaying ICA
  • Able to provide written informed consent

Exclusion Criteria

  • Contraindications for CMR examination with gadolinium contrast (claustrophobia, eGFR \<30ml/min/1.73m2, contrast allergy, and non-MRI compatible implants)
  • Arrythmias which hinder CMR examination
  • Previous CABG
  • Hemodynamic instability
  • Myocardial infarction \<6 months prior to inclusion

Outcomes

Primary Outcomes

Rate of IRA territory reclassification

Time Frame: Every three months, until study completion

One primary outcome measurement will be to what extent a CMR examination can reclassify the IRA (infarct-related artery) territory established on ICA, by designating a new IRA based on the area of infarction on CMR using the 17-segment model of the American Heart Association and magnetic resonance angiography

Rate of non-ischemic diagnosis

Time Frame: Every three months, until study completion

In cases where CMR establishes a diagnosis which is non-ischemic in nature, such as a myocarditis, an ICA can be deferred since a diagnosis has been made using CMR.

Study Sites (1)

Loading locations...

Similar Trials